

# CITATION REPORT

List of articles citing

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

DOI: 10.1038/sj.ijo.0803344

International Journal of Obesity, 2006, 30, 1729-36.

**Source:** <https://exaly.com/paper-pdf/41031362/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
271	The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. <b>2006</b> , 2, 612-20		56
270	Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. <b>2006</b> , 350, 298-306		70
269	The obesity pipeline: current strategies in the development of anti-obesity drugs. <b>2006</b> , 5, 919-31		164
268	Gastrointestinal regulation of food intake. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 13-23	15.9	806
267	Appetite regulation: an overview. <b>2007</b> , 17, 433-45		86
266	Gut hormones and appetite control. <b>2007</b> , 132, 2116-30		315
265	Gut hormones regulating appetite and metabolism. <b>2007</b> , 4, 147-151		2
264	Hormonal regulation of appetite. <b>2007</b> , 8 Suppl 1, 63-5		10
263	Pharmacotherapy for obesity. <b>2007</b> , 9, 454-62		10
262	Central control of body weight and appetite. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, S37-50	5.6	300
261	The effects of pancreatic polypeptide on locomotor activity and food intake in mice. <i>International Journal of Obesity</i> , <b>2008</b> , 32, 1712-5	5.5	15
260	Gastrointestinal satiety signals. <i>International Journal of Obesity</i> , <b>2008</b> , 32 Suppl 7, S28-31	5.5	44
259	Bariatric surgery for extreme adolescent obesity: indications, outcomes, and physiologic effects on the gut-brain axis. <b>2008</b> , 15, 135-46		27
258	Gut hormones as potential new targets for appetite regulation and the treatment of obesity. <b>2008</b> , 68, 147-63		19
257	Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. <b>2008</b> , 5, 268-77		50
256	Gastrointestinal satiety signals. <b>2008</b> , 70, 239-55		128
255	Can gut hormones control appetite and prevent obesity?. <b>2008</b> , 31 Suppl 2, S284-9		46

254	The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. <b>2008</b> , 149, 5670-8	85
253	Hormone-based therapies in the regulation of fuel metabolism and body weight. <b>2008</b> , 8, 1733-47	11
252	Neuroendocrine regulation of food intake. <b>2008</b> , 24, 223-9	14
251	Crystallization and preliminary x-ray analysis of anti-obesity peptide hormone oxyntomodulin. <b>2008</b> , 15, 232-4	1
250	Obesity: the hormonal milieu. <b>2008</b> , 15, 9-20	22
249	Bibliography. Current world literature. Growth and development. <b>2008</b> , 15, 79-101	
248	Obesity and diabetes. <b>2008</b> , 21-49	1
247	Oxintomodulina e obesidade. <b>2009</b> , 22, 727-737	5
246	Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. <b>2009</b> , 76, 199-206	98
245	Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. <b>2009</b> , 150, 1712-22	73
244	Drug treatment of obesity: established and emerging therapies. <b>2009</b> , 9, 664-73	30
243	Gut hormones: implications for the treatment of obesity. <b>2009</b> , 124, 44-56	101
242	Obesity treatment: novel peripheral targets. <b>2009</b> , 68, 830-43	49
241	Gut hormones and appetite control. <b>2009</b> , 15, 18-26	64
240	Satiation, satiety and their effects on eating behaviour. <b>2009</b> , 34, 126-173	192
239	Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. <b>2009</b> , 58, 2258-66	289
238	Metabolic surgery and gut hormones - a review of bariatric entero-humoral modulation. <b>2009</b> , 97, 620-31	75
237	Anti-obesity agents: a focused review on the structural classification of therapeutic entities. <b>2009</b> , 9, 466-81	18

236	Gut-brain cross-talk in appetite regulation. <b>2010</b> , 13, 588-93		14
235	Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options. <i>Pharmaceuticals</i> , <b>2010</b> , 3, 125-145	5.2	6
234	The role of gut hormones and the hypothalamus in appetite regulation. <b>2010</b> , 57, 359-72		190
233	New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?. <b>2010</b> , 97, 63-83		56
232	(D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. <b>2010</b> , 80, 1727-35		47
231	Sizing up pharmacotherapy for obesity. <b>2010</b> , 3, 123-5		2
230	Central and peripheral molecular targets for antiobesity pharmacotherapy. <b>2010</b> , 87, 652-62		37
229	Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. <i>International Journal of Obesity</i> , <b>2010</b> , 34, 1715-25	5.5	40
228	Physiology of Weight Regulation. <b>2010</b> , 9-12		
227	Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. <i>European Journal of Endocrinology</i> , <b>2010</b> , 162, 75-83	6.5	24
226	Brain imaging studies of appetite in the context of obesity and the menstrual cycle. <b>2010</b> , 16, 276-92		47
225	Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. <b>2010</b> , 5, 765-783		3
224	Approaches to the pharmacological treatment of obesity. <b>2010</b> , 3, 73-88		10
223	Gastrointestinal symptoms and diseases related to obesity: an overview. <b>2010</b> , 39, 23-37		15
222	Pharmacological management of appetite expression in obesity. <b>2010</b> , 6, 255-69		98
221	Appetite and hedonism: gut hormones and the brain. <b>2010</b> , 39, 729-43		17
220	Bowels control brain: gut hormones and obesity. <b>2010</b> , 6, 444-53		129
219	The role of gut hormones in the regulation of body weight and energy homeostasis. <b>2010</b> , 316, 120-8		154

218	Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. <b>2011</b> , 301, R15-27		74
217	Emerging therapies in the treatment of <b>Diabetes</b> beyond GLP-1. <b>2011</b> , 32, 8-15		32
216	Gastrointestinal Hormones and Obesity. <b>2011</b> , 109-125		
215	Management of type 2 diabetes: new and future developments in treatment. <b>2011</b> , 378, 182-97		398
214	Gut as an Endocrine Organ: The Role of Nutrient Sensing in Energy Metabolism. <b>2011</b> , 1-28		1
213	The gut hormones in appetite regulation. <b>2011</b> , 2011, 528401		52
212	Pharmacotherapy for obesity: a field in crisis?. <b>2011</b> , 6, 563-577		4
211	DPP-IV-resistant, long-acting oxyntomodulin derivatives. <b>2011</b> , 17, 270-80		53
210	The pharmacological treatment and management of obesity. <b>2011</b> , 123, 34-44		31
209	Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2227-35	5.6	249
208	Regulation of appetite to treat obesity. <b>2011</b> , 4, 243-59		32
207	Current and emerging concepts on the role of peripheral signals in the control of food intake and development of obesity. <b>2012</b> , 108, 778-93		36
206	Unraveling oxyntomodulin, GLP1's enigmatic brother. <b>2012</b> , 215, 335-46		94
205	Obesity and appetite control. <b>2012</b> , 2012, 824305		132
204	Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. <b>2012</b> , 9, 705-15		31
203	The role of the gut/brain axis in modulating food intake. <b>2012</b> , 63, 46-56		107
202	Central control of thermogenesis. <b>2012</b> , 63, 111-23		73
201	Gut hormones: the future of obesity treatment?. <b>2012</b> , 74, 911-9		17

200	The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. <b>2012</b> , 20, 1566-71		76
199	Determination of oxyntomodulin, an anorectic polypeptide, in rat plasma using 2D-LC-MS/MS coupled with ion pair chromatography. <b>2012</b> , 903, 102-11		19
198	Improvement in <del>cell</del> function after diet-induced weight loss is associated with decrease in pancreatic polypeptide in subjects with type 2 diabetes. <b>2012</b> , 26, 442-9		25
197	Ghrelin in Cachexia Associated with End-Stage Renal Disease. <b>2012</b> , 231-256		
196	Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. <b>2012</b> , 303, E265-71		40
195	Gut hormones and leptin: impact on energy control and changes after bariatric surgery--what the future holds. <b>2012</b> , 22, 1648-57		37
194	Pharmacological Treatment of Obesity. <b>2012</b> , 203-225		2
193	The regulation of food intake by the gut-brain axis: implications for obesity. <i>International Journal of Obesity</i> , <b>2013</b> , 37, 625-33	5.5	130
192	Metabolic Effects of Bariatric Surgery: A Focus on Inflammation and Diabetic Kidney Disease. <i>Current Obesity Reports</i> , <b>2013</b> , 2, 120-127	8.4	1
191	Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. <b>2013</b> , 25, 597-604		22
190	G protein-coupled receptors as regulators of energy homeostasis. <b>2013</b> , 114, 1-43		13
189	Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. <b>2013</b> , 91, 1009-15		28
188	A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates. <b>2013</b> , 56, 8339-51		14
187	Gut hormones as therapeutic agents in treatment of diabetes and obesity. <b>2013</b> , 13, 996-1001		42
186	Oxyntomodulin increases intrinsic heart rate through the glucagon receptor. <b>2013</b> , 1, e00112		11
185	Obesity pharmacotherapy: what is next?. <b>2013</b> , 34, 71-83		45
184	The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. <b>2013</b> , 62, 457-78		216
183	A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. <b>2013</b> , 21, 7064-73		36

182	Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. <b>2013</b> , 9, 425-33	136
181	Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release. <b>2013</b> , 169, 671-84	62
180	Treating the obese diabetic. <b>2013</b> , 6, 171-83	6
179	Gut hormones and obesity: physiology and therapies. <b>2013</b> , 91, 143-94	16
178	Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. <b>2013</b> , 62, 1131-8	134
177	A novel GIP-oxytomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. <b>2013</b> , 85, 1655-62	59
176	Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabetes. <b>2013</b> , 23, 4011-8	104
175	Evaluations of Actiheart, IDEEA <sup>®</sup> and RT3 monitors for estimating activity energy expenditure in free-living women. <b>2013</b> , 2, e31	3
174	New advances in models and strategies for developing anti-obesity drugs. <b>2013</b> , 8, 655-71	18
173	Satiety signals and obesity. <b>2013</b> , 29, 222-7	39
172	Incretins: new targets for the prevention of diabetes and obesity. <b>2013</b> , 8, 109-121	1
171	The role of hormonal factors in weight loss and recidivism after bariatric surgery. <b>2013</b> , 2013, 528450	26
170	Obesity pharmacotherapy: current perspectives and future directions. <b>2013</b> , 9, 33-54	12
169	Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy. <b>2014</b> , 3, 763-94	8
168	The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. <b>2014</b> , 9, 69-76	23
167	Gut hormones and Type 2 diabetes mellitus. <b>2014</b> , 4, 501-513	2
166	The role of gut hormones in appetite regulation (review). <b>2014</b> , 101, 395-407	29
165	New molecular targets in the pathophysiology of obesity and available treatment options under investigation. <b>2014</b> , 4, 209-19	3

164	Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. <b>2014</b> , 9, 61-72		22
163	Action and therapeutic potential of oxyntomodulin. <i>Molecular Metabolism</i> , <b>2014</b> , 3, 241-51	8.8	106
162	The future role of gut hormones in the treatment of obesity. <b>2014</b> , 5, 4-14		90
161	Neuroendocrinology of obesity. <b>2014</b> , 109, 73-82		9
160	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. <b>2014</b> , 383, 1068-83		915
159	The relationship between gut and adipose hormones, and reproduction. <b>2014</b> , 20, 153-74		85
158	Can Bayliss and Starling gut hormones cure a worldwide pandemic?. <b>2014</b> , 592, 5153-67		5
157	Models and strategies in the development of antiobesity drugs. <b>2014</b> , 51, 695-706		7
156	The forgotten members of the glucagon family. <b>2014</b> , 106, 1-10		23
155	Comparison of stability, cellular, glucose-lowering and appetite suppressing effects of oxyntomodulin analogues modified at the N-terminus. <b>2014</b> , 743, 69-78		20
154	Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. <b>2014</b> , 63, 3711-20		92
153	Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats. <b>2015</b> , 77, 111-5		4
152	Food preferences and underlying mechanisms after bariatric surgery. <b>2015</b> , 74, 419-25		58
151	The L-Cell in Nutritional Sensing and the Regulation of Appetite. <b>2015</b> , 2, 23		112
150	Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development. <b>2015</b> , 11, 17-31		39
149	Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones. <b>2015</b> , 127, 494-502		14
148	Regulation of appetite, satiation, and body weight by enteroendocrine cells. Part 1: characteristics of enteroendocrine cells and their capability of weight regulation. <b>2015</b> , 83, 1-10		22
147	Increased food intake with oxyntomodulin analogues. <i>Peptides</i> , <b>2015</b> , 73, 95-100	3.8	5



146	The gut sensor as regulator of body weight. <b>2015</b> , 49, 35-50		22
145	Treatment of obesity: bariatric surgery. <b>2015</b> , 505-518		1
144	New perspectives on the development of antiobesity drugs. <b>2015</b> , 7, 315-36		4
143	Effect of Oxymetazolin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 4541-52	5.6	51
142	Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic $\beta$ Cells. <b>2015</b> , 175-247		1
141	Peripheral mechanisms in appetite regulation. <b>2015</b> , 148, 1219-33		119
140	Update on the treatment of type 2 diabetes mellitus. <b>2016</b> , 7, 354-95		269
139	Physiology of Weight Regulation. <b>2016</b> , 1-4		1
138	The metabolic vascular syndrome - guide to an individualized treatment. <b>2016</b> , 17, 5-17		25
137	Comment on "Decreased serum betatrophin levels correlate with improved fasting plasma glucose and insulin secretion capacity after Roux-en-Y gastric bypass in obese Chinese patients with type 2 diabetes: a 1-year follow-up". <b>2016</b> , 12, 1349-1350		
136	Food Intake, Circuitry, and Energy Metabolism. <b>2016</b> , 355-373		
135	Microbial regulation of GLP-1 and L-cell biology. <i>Molecular Metabolism</i> , <b>2016</b> , 5, 753-8	8.8	71
134	Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabetes. <b>2016</b> , 95, 5-9		16
133	Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats. <b>2016</b> , 45, 967-73		
132	Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 1176-1190	6.7	132
131	Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake. <b>2016</b> , 11, 475-499		13
130	The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight. <b>2016</b> , 18, 49		15
129	Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. <b>2016</b> , 27, 689-711		18

128 Anstöße wider den großen Appetit. **2016**, 10, 47-53

127 Metabolism and Mental Illness. **2016**, 22, 174-183

12

126 Postprandial effects of consuming a staggered meal on gut peptide and glycemic responses in obese women and men. **2016**, 10, 264-74

125 Role of gastrointestinal hormones in feeding behavior and obesity treatment. **2016**, 51, 93-103

16

124 The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. *Peptides*, **2016**, 77, 28-37

3.8 160

123 Glucagon and the Glucagon-Like Peptides. **2016**, 586-597.e5

122 The Role of Gut-brain Axis in Regulating Glucose Metabolism After Acute Pancreatitis. *Clinical and Translational Gastroenterology*, **2017**, 8, e210

4.2 33

121 New Targets for Drug Treatment of Obesity. **2017**, 57, 585-605

28

120 Central and peripheral control of food intake. **2017**, 51, 52-70

39

119 The New Biology and Pharmacology of Glucagon. **2017**, 97, 721-766

142

118 The Importance of the Gastrointestinal Tract in Controlling Food Intake and Regulating Energy Balance. **2017**, 152, 1707-1717.e2

53

117 Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. **2017**, 60, 4293-4303

69

116 The Physiology and Molecular Underpinnings of the Effects of Bariatric Surgery on Obesity and Diabetes. **2017**, 79, 313-334

56

115 The modulatory roles of oxyntomodulin and glucagon-like peptide 1 administered spinally in the regulation of the blood glucose level. **2017**, 11, 57-62

114 The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2364-2372

5.6 55

113 GLP-1/glucagon receptor co-agonism for treatment of obesity. **2017**, 60, 1851-1861

84

112 Potential Hormone Mechanisms of Bariatric Surgery. *Current Obesity Reports*, **2017**, 6, 253-265

8.4 79

111 Gut check on diabetes: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity. **2017**, 37, 10-15

7

110	Neural circuits of eating behaviour: Opportunities for therapeutic development. <b>2017</b> , 31, 1388-1402		9
109	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. <i>Trends in Endocrinology and Metabolism</i> , <b>2017</b> , 28, 88-103	8.8	61
108	A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. <b>2017</b> , 65, 950-968		49
107	Antinociceptive profiles and mechanisms of centrally administered oxyntomodulin in various mouse pain models. <b>2018</b> , 68, 7-14		4
106	Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. <i>Cell Metabolism</i> , <b>2018</b> , 27, 740-756	24.6	441
105	Gut hormone polyagonists for the treatment of type 2 diabetes. <i>Peptides</i> , <b>2018</b> , 100, 190-201	3.8	70
104	Problem or solution: The strange story of glucagon. <i>Peptides</i> , <b>2018</b> , 100, 36-41	3.8	24
103	Oxyntomodulin: Actions and role in diabetes. <i>Peptides</i> , <b>2018</b> , 100, 48-53	3.8	40
102	Intestinal peptide changes after bariatric and minimally invasive surgery: Relation to diabetes remission. <i>Peptides</i> , <b>2018</b> , 100, 114-122	3.8	16
101	Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia. <b>2018</b> , 98, 364-371		7
100	Oxyntomodulin analogue increases energy expenditure via the glucagon receptor. <i>Peptides</i> , <b>2018</b> , 104, 70-77	3.8	23
99	Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes. <b>2018</b> , 67, 1105-1112		28
98	Hormones and Gastrointestinal Function of Newborns. <b>2018</b> , 535-555		
97	Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198024	3.7	13
96	Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1836-1851	6.7	16
95	MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. <b>2018</b> , 391, 2607-2618		149
94	Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. <b>2018</b> , 159, 3105-3119		15
93	The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity. <b>2018</b> , 9, 900		79

92	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 442	5.7	12
91	Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. <b>2018</b> , 70, 712-746		82
90	Gastrointestinal Hormones ?. <b>2018</b> , 31-70		15
89	MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. <b>2018</b> , 84, 2325-2335		32
88	A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 120-128	6.7	84
87	Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects. <b>2019</b> , 17, 7760-7771		3
86	Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. <b>2019</b> , 101, 153997		33
85	The Microbiota-Gut-Brain Axis. <b>2019</b> , 99, 1877-2013		979
84	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. <b>2019</b> , 100, 153960		12
83	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. <b>2019</b> , 42, 1446-1453		47
82	Effect of physical exercise and training on gastrointestinal hormones in populations with different weight statuses. <b>2019</b> , 77, 455-477		12
81	Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?. <b>2019</b> , 10, 457		16
80	Measurement of Energy Expenditure. <b>2019</b> , 101-119		1
79	The role of gut hormones in obesity. <b>2019</b> , 4, 4-13		9
78	Pharmacotherapy of obesity: Available medications and drugs under investigation. <b>2019</b> , 92, 170-192		98
77	The Regulation of Peripheral Metabolism by Gut-Derived Hormones. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 754	5.7	23
76	Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity. <b>2019</b> , 13, 586-601		22
75	Co-ingestion of whey protein hydrolysate with milk minerals rich in calcium potently stimulates glucagon-like peptide-1 secretion: an RCT in healthy adults. <b>2020</b> , 59, 2449-2462		4

74	Developmental Origins and Roles of Intestinal Enteroendocrine Hormones. <b>2020</b> , 599-610		
73	Intestinal Hormones. <b>2020</b> , 361-381		
72	Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 640-647	6.7	14
71	Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor/glucagon receptor dual agonists. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2437-2450	6.7	9
70	Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity. <i>MAbs</i> , <b>2020</b> , 12, 1794687	6.6	3
69	Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome. <i>Current Diabetes Reports</i> , <b>2020</b> , 20, 26	5.6	9
68	The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications. <i>Current Obesity Reports</i> , <b>2020</b> , 9, 136-149	8.4	9
67	Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. <i>Nature Metabolism</i> , <b>2020</b> , 2, 413-431	14.6	47
66	Glucagon-based therapy: Past, present and future. <i>Peptides</i> , <b>2020</b> , 127, 170296	3.8	8
65	Leveraging the Gut to Treat Metabolic Disease. <i>Cell Metabolism</i> , <b>2020</b> , 31, 679-698	24.6	19
64	New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. <i>Bioconjugate Chemistry</i> , <b>2020</b> , 31, 1167-1176	6.3	14
63	The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity. <i>Current Obesity Reports</i> , <b>2020</b> , 9, 255-271	8.4	12
62	Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	24
61	From Entero-Endocrine Cell Biology to Surgical Interventional Therapies for Type 2 Diabetes. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1307, 273-297	3.6	2
60	Oxyntomodulin May Distinguish New-Onset Diabetes After Acute Pancreatitis From Type 2 Diabetes. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00132	4.2	12
59	Drug Therapy in Obesity: A Review of Current and Emerging Treatments. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 1199-1216	3.6	56
58	Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF- $\beta$ Superfamily Hormones in PCOS. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 108-119	5.6	2
57	Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	7

56	Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes. <b>2021</b> ,		1
55	Association of Gut Hormones and Microbiota with Vascular Dysfunction in Obesity. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	8
54	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23 Suppl 1, 17-35	6.7	4
53	Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	7
52	Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake. <i>Comprehensive Physiology</i> , <b>2021</b> , 11, 1679-1730	7.7	7
51	Glucagon-Like Peptide-1 Receptor Activators. 1-69		
50	S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabetes and renal injury through activating GLP-1 and glucagon receptors. <i>Life Sciences</i> , <b>2021</b> , 270, 119136	6.8	0
49	Proglucagon-Derived Peptides as Therapeutics. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 689678	5.7	7
48	Old Paradoxes and New Opportunities for Appetite Control in Obesity. <i>Trends in Endocrinology and Metabolism</i> , <b>2021</b> , 32, 264-294	8.8	7
47	Thermo-Responsive self-assembly of a dual glucagon-like peptide and glucagon receptor agonist. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 604, 120719	6.5	0
46	The metabolomic effects of tripeptide gut hormone infusion compared to Roux-en-Y gastric bypass and caloric restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	3
45	New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. <i>Pharmaceutics</i> , <b>2021</b> , 14,	5.2	3
44	MECHANISMS IN ENDOCRINOLOGY: The gut-brain axis: regulating energy balance independent of food intake. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, R75-R91	6.5	4
43	Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
42	Measurement of Energy Expenditure. <b>2015</b> , 169-187		2
41	Environmental Inputs, Intake of Nutrients, and Endogenous Molecules Contributing to the Regulation of Energy Homeostasis. <b>2009</b> , 41-75		1
40	The Gut and Type 2 Diabetes Mellitus. <b>2020</b> , 375-393		1
39	Bowels control brain: gut hormones and obesity. <i>Biochimica Medica</i> , <b>2012</b> , 22, 283-97	2.5	16

38	The role of gut hormones in glucose homeostasis. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 24-32	15.9	436
37	The Role of the Gastrointestinal Tract in Satiety, Satiety, and Food Intake. <b>2008</b> , 187-211		6
36	Therapy for obesity based on gastrointestinal hormones. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 339-47	3.6	8
35	GLP-1 physiology informs the pharmacotherapy of obesity. <i>Molecular Metabolism</i> , <b>2021</b> , 57, 101351	8.8	9
34	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , <b>2021</b> ,	27.2	4
33	Gut Hormones and Energy Balance, The Future for Obesity Therapy?. <i>Indonesian Biomedical Journal</i> , <b>2009</b> , 1, 33	2.6	
32	Glucagon and the Glucagon-Like Peptides. <b>2010</b> , 660-672		
31	Pharmacotherapy of Childhood Obesity and Pre-diabetes. <b>2010</b> , 339-355		
30	Hormones and Gastrointestinal Function. <b>2012</b> , 281-289		
29	Food Intake and Gut Hormones. <i>The Korean Journal of Obesity</i> , <b>2013</b> , 22, 197		
28	Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic $\beta$ Cells. <b>2014</b> , 1-69		2
27	Gut Peptides. <b>2014</b> , 37-55		
26	Obesity research: Status quo and future outlooks. <i>World Journal of Translational Medicine</i> , <b>2014</b> , 3, 119		8
25	Concept of Metabolic Surgery. <b>2014</b> , 47-66		
24	Hormones and Gastrointestinal Function of Newborns. <b>2016</b> , 1-20		1
23	Mechanisms of Action of Bariatric Surgical Procedures. <b>2016</b> , 519-527		
22	Hypothalamic Obesity and Wasting Syndromes. <i>Contemporary Endocrinology</i> , <b>2021</b> , 235-280	0.3	
21	Exercise and Training Effects on Appetite-Regulating Hormones in Individuals with Obesity. <i>Contemporary Endocrinology</i> , <b>2020</b> , 535-562	0.3	1

20 Gut Peptides. **2014**, 37-55

0

19 A glucagon analogue decreases body weight in mice via signalling in the liver. *Scientific Reports*, **2021**, 11, 22577

4.9 1

18 Novel Drugs for Diabetes Therapy.. *Handbook of Experimental Pharmacology*, **2022**, 1

3.2

17 Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes.. *Clinical Pharmacokinetics*, **2022**,

6.2 0

16 Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery.. *International Journal of Molecular Sciences*, **2022**, 23,

6.3 1

15 Adjunctive Therapy, Including Pharmacotherapy. **2022**, 279-296

14 Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls.. *PLoS ONE*, **2022**, 17, e0264974

3.7 0

13 The Enteroendocrine System in Obesity.. *Handbook of Experimental Pharmacology*, **2022**, 1

3.2 0

12 Adipose tissue, systematic inflammation, and neurodegenerative diseases. *Neural Regeneration Research*, **2023**, 18, 38

4.5 0

11 The molecular signaling of exercise and obesity in the microbiota-gut-brain axis. *Frontiers in Endocrinology*, 13,

5.7 1

10 Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes. *ACS Medicinal Chemistry Letters*,

4.3 0

9 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. **2022**,

3

8 Brain Related Gut Peptides [A Review. **2022**, 29,

0

7 BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. **2022**, 101633

2

6 Development of a selective, sensitive and robust oxyntomodulin dual monoclonal antibody immunoassay.

0

5 Factors Affecting the Circulating Levels of Oxyntomodulin in Health and After Acute Pancreatitis. **2022**, 51, 774-783

0

4 Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor ( GCGR / GLP-1R ) agonist BI 456906.

0

3 Glucagon-like peptide -1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial. **2023**, 31, 350-362

1



2

Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy. **2023**, 162, 170962

o

1

Hormonal GutBrain Signaling for the Treatment of Obesity. **2023**, 24, 3384

o